Sam Blackman, Co-founder and Chief Medical Officer of Day One Biopharmaceuticals, shared a post by Day One Biopharmaceuticals, on X:

“Proud of the hard work from the Day One Biopharmaceuticals teams and the broader pediatric oncology community to make this achievement possible! We did it!”

Quoting Day One Biopharmaceuticals‘s post:

“We are proud to share the accelerated approval by the US FDA of the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation. ”

Source: Sam Blackman/X and Day One Biopharmaceuticals/X